Fertility treatment and risk of non-Hodgkin lymphoma – results from a Danish population-based cohort study
Authors:
- Anna Kjær KristensenAKAnna Kjær Kristensen
- Clarissa Lima Brown FrandsenCFClarissa Lima Brown Frandsen
- Maria MøllerMMMaria Møller
- Bugge NøhrBNBugge Nøhr
- Henrik HjalgrimHHHenrik Hjalgrim
- Jakob Hansen ViuffJVJakob Hansen Viuff
- Marie HargreaveMHMarie Hargreave
- Susanne Krüger KjærSKSusanne Krüger Kjær
- Allan JensenAJAllan Jensen
- 2 June 2025
- journal article
- research article
- Published by Springer Nature in Cancer Causes & Control
- Vol. 36 (10) , 1217-1225
Abstract
Purpose To investigate the association between fertility drug use and non-Hodgkin lymphoma. Methods This cohort study utilized data from the extensive Danish Infertility Cohort, comprising 148,036 women with fertility problems residing in Denmark between January 1, 1995 and December 31, 2017. The study cohort was linked to national registers to gather information on fertility drug use, cancer diagnoses, covariates, and emigration and vital status. Cox proportional hazard models were employed to calculate hazard ratios (HRs) and 95% confidence intervals for non-Hodgkin lymphoma (overall and for histologic subtypes), with adjustments for potential confounders. Results Over a median follow-up of 11.3 years, 115 women were diagnosed with non-Hodgkin lymphoma. After adjustment for potential confounders, overall non-Hodgkin lymphoma rates were decreased following treatment with all specific types of fertility drugs analyzed being clomiphene citrate (HR 0.74; 95% CI 0.43–1.26), gonadotropins (HR 0.67; 95% CI 0.39–1.16), hCG (HR 0.69; 95% CI 0.41–1.17), GnRH receptor modulators (HR 0.58; 95% CI 0.33–1.03), and progesterone (HR 0.69; 95% CI 0.39–1.21). However, none of these associations were statistically significant implying that the results should be interpreted with great caution. Similar trends were seen for B-cell lymphomas. For most fertility drugs, we observed a tendency toward lower associations within the first 10 years after start of drug use. Conclusion The findings of this study do not indicate any strong associations between the use of fertility drugs and the risk of non-Hodgkin lymphoma. However, the relatively young age of the cohort at the end of follow-up underscores the need for an extended follow-up period to evaluate the long-term risk of non-Hodgkin lymphoma in women who have used fertility drugs.Keywords
Funding Information
- Danish Cancer Society (R309-A17906)
This publication has 31 references indexed in Scilit:
- Risk of colorectal cancer after use of fertility drugs—results from a large Danish population-based cohort of women with infertilityFertility and Sterility, 2022
- Use of Fertility Drugs and Risk of Malignant Melanoma: Results from a Large Danish Population-Based Cohort StudyJournal of Investigative Dermatology, 2021
- Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertilityCochrane Database of Systematic Reviews, 2019
- Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertilityCochrane Database of Systematic Reviews, 2017
- Effects of fertility drugs on cancers other than breast and gynecologic malignanciesFertility and Sterility, 2015
- Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studiesBreast Cancer Research and Treatment, 2015
- Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohortBritish Journal of Cancer, 2009
- Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish Population-based Cohort StudyBritish Journal of Cancer, 2006
- The epidemiology of non-Hodgkin lymphomaPathology, 2005
- Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa Women's Health Study (United States)Cancer Causes & Control, 2002